---
id: vaccination-principles_121
category: vaccines
tags: [vaccination, adult-immunization, live-vaccines, immunocompromised, vaccine-safety]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Vaccination Principles & Adult Immunization Schedule

**Q:** What are the key principles of vaccination (live vs inactivated), adult immunization schedule highlights, vaccine contraindications, and approach to immunocompromised patients?

**A:**

## VACCINE TYPES

### **LIVE ATTENUATED VACCINES**

**Mechanism:** Contain weakened (attenuated) live organisms that replicate in host

**Advantages:**
- **Strong, long-lasting immunity** (often lifelong after 1-2 doses)
- **Cellular + humoral immune response** (mimics natural infection)

**Disadvantages:**
- **Contraindicated in immunocompromised** (risk of disease from vaccine strain)
- **Risk of reversion to virulence** (rare)

**Live Vaccines:**
- **MMR** (measles, mumps, rubella)
- **Varicella** (chickenpox)
- **Zoster vaccine (Zostavax)** - DISCONTINUED in US (replaced by Shingrix)
- **Yellow fever**
- **Oral typhoid** (Vivotif)
- **Oral polio** (OPV - not used in US)
- **Intranasal influenza** (FluMist)
- **BCG** (not routinely used in US)

**Key Point:** **Live vaccines contraindicated if immunocompromised, pregnant** (except OPV in endemic areas)

---

### **INACTIVATED/SUBUNIT VACCINES**

**Mechanism:** Contain killed organisms, proteins, or polysaccharides (no replication)

**Advantages:**
- **Safe in immunocompromised** (cannot cause disease)
- **No reversion risk**

**Disadvantages:**
- **Weaker immune response** (multiple doses/boosters often needed)
- **No cellular immunity** (humoral only)

**Inactivated Vaccines:**
- **Influenza** (injectable)
- **Hepatitis A, Hepatitis B**
- **Tdap** (tetanus, diphtheria, pertussis)
- **Pneumococcal** (PCV20, PPSV23)
- **HPV** (Gardasil 9)
- **Meningococcal** (MenACWY, MenB)
- **Polio** (IPV - inactivated)
- **Rabies**
- **COVID-19** (mRNA, protein subunit)
- **RSV** (Abrysvo, Arexvy)
- **Shingrix** (recombinant zoster vaccine - **preferred**)

**Key Point:** **Inactivated vaccines safe in immunocompromised** (but may have reduced efficacy)

---

## GENERAL VACCINATION PRINCIPLES

**Simultaneous Administration:**
- **Inactivated vaccines:** Can be given simultaneously OR at any interval
- **Live vaccines:** Give simultaneously OR **≥28 days apart** (if not simultaneous)

**Spacing Example:**
- **MMR + Varicella:** Give same day OR wait ≥28 days between doses
- **Influenza + Pneumococcal:** Can give same day (both inactivated)

**Key Point:** **Live vaccines = same day OR ≥28 days apart** (inactivated = any interval)

---

## ADULT IMMUNIZATION SCHEDULE (2024 HIGHLIGHTS)

### **1. INFLUENZA**

**Recommendation:** **Annual vaccination for ALL adults** (September-October optimal timing)

**Vaccine Options:**
- **Standard-dose** (18-64 years)
- **High-dose OR adjuvanted** (≥65 years) - **preferred** (better efficacy)

**Key Point:** **Annual influenza vaccine for ALL adults** (high-dose preferred for ≥65 years)

---

### **2. COVID-19**

**Recommendation (2024):** **≥1 dose of updated COVID-19 vaccine** (all adults)

**Special Populations:**
- **Immunocompromised:** Additional doses (per current CDC guidance)

**Key Point:** **Updated COVID-19 vaccine recommended annually** (per current strain)

---

### **3. TDAP (Tetanus, Diphtheria, Pertussis)**

**Recommendation:**
- **Tdap x 1 dose** (if not previously received as adult)
- **Td booster every 10 years**

**Pregnancy:** **Tdap during each pregnancy** (27-36 weeks) - protects newborn

**Key Point:** **Tdap every pregnancy** (27-36 weeks) + Td booster every 10 years

---

### **4. MMR (Measles, Mumps, Rubella)**

**Recommendation:**
- **1-2 doses** (if born ≥1957 and no immunity documented)
- **Healthcare workers, international travelers:** **2 doses** (separated by ≥28 days)

**Contraindications:**
- **Pregnancy, immunocompromised**

**Key Point:** **MMR = live vaccine** (2 doses for healthcare workers, international travelers)

---

### **5. VARICELLA (Chickenpox)**

**Recommendation:** **2 doses** (if no history of chickenpox or vaccination)

**Contraindications:**
- **Pregnancy, immunocompromised**

**Key Point:** **Varicella vaccine if no history of chickenpox** (2 doses, 4-8 weeks apart)

---

### **6. ZOSTER (Shingles) - SHINGRIX (Preferred)**

**Recommendation:** **2 doses (Shingrix)** - **all adults ≥50 years**

**Vaccine:** **Recombinant zoster vaccine (RZV)** - Shingrix
- **Inactivated** (safe in immunocompromised)
- **2 doses IM** (2-6 months apart)
- **Efficacy:** >90% (vs 50% for Zostavax)

**Indications:**
- **≥50 years** (routine)
- **Immunocompromised ≥19 years** (safe - inactivated vaccine)
- **Prior varicella vaccine or history of shingles** (still recommend)

**Key Point:** **Shingrix ≥50 years** (2 doses, 2-6 months apart, **safe in immunocompromised**)

---

### **7. PNEUMOCOCCAL**

**2024 Updated Recommendation:**

**Age ≥65 years OR High-Risk (19-64 years):**
- **PCV20** (Prevnar 20) **single dose** - **preferred** (covers 20 serotypes, lifelong protection)
- **OR PCV15 (Vaxneuvance) → followed by PPSV23 (≥1 year later)**

**High-Risk Conditions:**
- **Chronic heart/lung/liver disease, diabetes, asplenia, CSF leak, cochlear implant, immunocompromised**

**Key Point:** **PCV20 single dose ≥65 years** (preferred, lifelong protection)

---

### **8. HEPATITIS A**

**Recommendation:**
- **2 doses** (0, 6-12 months) - all adults who request it OR have risk factors

**Risk Factors:**
- **Chronic liver disease (HBV, HCV, cirrhosis)**
- **MSM, IVDU**
- **Travel to endemic areas**
- **Occupational exposure** (healthcare, food handlers)

**Key Point:** **Hepatitis A = 2 doses** (all adults with risk factors OR who request it)

---

### **9. HEPATITIS B**

**Recommendation:** **3 doses** (0, 1, 6 months) - **universal adult vaccination** (up to age 59 years, ≥60 years with risk factors)

**2024 Update:** Universal vaccination for **all adults 19-59 years** (not just risk-based)

**Risk Factors (≥60 years):**
- **Healthcare workers, IVDU, MSM, chronic liver disease, ESRD/dialysis**

**Vaccine Options:**
- **Standard 3-dose** (Engerix-B, Recombivax HB)
- **2-dose** (Heplisav-B) - 2 doses 1 month apart (**improved compliance**)

**Key Point:** **Universal hepatitis B vaccination 19-59 years** (2024 update)

---

### **10. HPV (Human Papillomavirus)**

**Recommendation:**
- **Routine:** **11-26 years** (2-3 doses depending on age at initiation)
- **Shared decision-making:** **27-45 years** (if not previously vaccinated)

**Vaccine:** **Gardasil 9** (9-valent) - protects against HPV types causing **cervical cancer, genital warts**

**Key Point:** **HPV vaccine 11-26 years** (prevent cervical cancer, genital warts)

---

### **11. MENINGOCOCCAL**

**Recommendation:**

**MenACWY (Quadrivalent):**
- **First-year college students** (if not vaccinated at ≥16 years)
- **Asplenia, complement deficiency, HIV, eculizumab** (2 doses, booster every 5 years)
- **Travel to endemic areas** (sub-Saharan Africa "meningitis belt", Hajj)

**MenB (Serogroup B):**
- **Asplenia, complement deficiency, eculizumab** (2-3 doses, booster every 2-3 years)
- **Outbreak settings** (college campuses)

**Key Point:** **Meningococcal vaccine for asplenia, complement deficiency** (MenACWY + MenB)

---

### **12. RSV (Respiratory Syncytial Virus)**

**2024 New Recommendation:**

**Recommendation:**
- **Single dose ≥60 years** (shared clinical decision-making based on risk factors)

**Vaccine Options:**
- **RSVPreF3 (Arexvy - GSK)** - single IM dose
- **RSVpreF (Abrysvo - Pfizer)** - single IM dose

**High-Risk:** Chronic lung/heart disease, immunocompromised, nursing home residents

**Key Point:** **RSV vaccine ≥60 years** (single dose, especially if chronic lung/heart disease)

---

## VACCINATION IN IMMUNOCOMPROMISED PATIENTS

### **General Principles:**

**Live Vaccines:**
- **CONTRAINDICATED** if severely immunocompromised (CD4 <200, chemotherapy, biologics, high-dose steroids)
- **Exceptions:** MMR/Varicella may be given if **mild immunosuppression** (e.g., low-dose prednisone <20 mg/day)

**Inactivated Vaccines:**
- **SAFE** (but may have **reduced efficacy**)
- **Give before immunosuppression if possible** (better immune response)

---

### **Vaccine Timing by Immunosuppression Type:**

| **Immunosuppression Type** | **Live Vaccine Timing** | **Inactivated Vaccine Timing** |
|----------------------------|-------------------------|--------------------------------|
| **High-dose steroids** (≥20 mg/day prednisone x ≥2 weeks) | **Wait 1 month** after stopping | Give anytime |
| **Chemotherapy** (solid tumor) | **Wait 3 months** after completing | Give anytime (may have reduced response) |
| **Hematopoietic stem cell transplant (HSCT)** | **Wait ≥24 months** post-transplant (if no GVHD) | Start at **6 months** post-transplant |
| **Solid organ transplant** | **Generally avoid** (lifelong immunosuppression) | Give anytime (reduced efficacy) |
| **Biologics** (anti-TNF, rituximab) | **Wait 3-6 months** after last dose | Give anytime (reduced efficacy, especially rituximab) |
| **HIV (CD4 <200)** | **Contraindicated** (except if CD4 >200) | Give anytime |

**Key Point:** **Wait 1-3 months after stopping immunosuppression** before giving live vaccines

---

### **HIV-Specific Vaccination Recommendations:**

| **Vaccine** | **CD4 Threshold** | **Recommendation** |
|-------------|-------------------|---------------------|
| **MMR, Varicella** | **CD4 ≥200** | Safe to give (live vaccines) |
| **Shingrix (RZV)** | **Any CD4** | Safe (inactivated) - 2 doses |
| **Pneumococcal** | **Any CD4** | **PCV20 x 1 dose** OR PCV15 → PPSV23 |
| **Hepatitis A/B** | **Any CD4** | Recommend (higher risk of complications) |

**Key Point:** **HIV: MMR/Varicella safe if CD4 ≥200** (live vaccines)

---

## VACCINE CONTRAINDICATIONS

### **Absolute Contraindications:**

| **Vaccine** | **Contraindication** |
|-------------|----------------------|
| **ALL vaccines** | **Severe allergic reaction** to prior dose or vaccine component |
| **Live vaccines** (MMR, varicella, yellow fever) | **Pregnancy, severe immunocompromise** (CD4 <200, chemotherapy, biologics) |
| **Yellow fever** | **Age <6 months** (risk of encephalitis)<br>**Thymus disorder** (myasthenia gravis, thymoma)<br>**Severe egg allergy** |
| **Influenza (egg-based)** | **Severe egg allergy** (can use recombinant or cell-based vaccine) |

**Key Point:** **Severe allergic reaction = contraindication to all vaccines** (prior dose or component)

---

### **Precautions (NOT Contraindications):**

**Common Misconceptions:**
- **Mild illness** (URI, low-grade fever) - **NOT a contraindication** (can vaccinate)
- **Antibiotic use** - **NOT a contraindication** (except oral typhoid - live vaccine affected by antibiotics)
- **Breastfeeding** - **NOT a contraindication** (safe for mother + infant)
- **Recent exposure to infectious disease** - **NOT a contraindication** (may even provide post-exposure prophylaxis, e.g., MMR, varicella)

**Key Point:** **Mild illness NOT a contraindication** (can vaccinate)

---

## SPECIAL SITUATIONS

### **ASPLENIA / HYPOSPLENIA**

**High-Risk Pathogens:** Encapsulated bacteria (*S. pneumoniae, H. influenzae, N. meningitidis*)

**Recommended Vaccines:**
- **Pneumococcal:** **PCV20 x 1 dose** (preferred)
- **MenACWY:** 2 doses (2 months apart) → **booster every 5 years**
- **MenB:** 2 doses (depending on vaccine) → **booster every 2-3 years**
- **Hib** (if not previously vaccinated)

**Key Point:** **Asplenia = PCV20 + MenACWY + MenB** (encapsulated bacteria risk)

---

### **PREGNANCY**

**Safe Vaccines:**
- **Tdap** (27-36 weeks - **every pregnancy**)
- **Influenza** (any trimester)
- **Inactivated vaccines** (hepatitis A/B, pneumococcal)
- **RSV** (Abrysvo) - single dose 32-36 weeks (or nirsevimab for infant)

**Contraindicated Vaccines:**
- **Live vaccines** (MMR, varicella, yellow fever, oral typhoid)

**Key Point:** **Tdap every pregnancy** (27-36 weeks) + annual influenza vaccine

---

### **HEALTHCARE WORKERS**

**Required/Strongly Recommended:**
- **MMR** (2 doses if born ≥1957)
- **Varicella** (2 doses OR documented immunity)
- **Influenza** (annual)
- **Hepatitis B** (3 doses + anti-HBs titer to confirm immunity)
- **Tdap** (if not previously received)

**Key Point:** **Healthcare workers: MMR (2 doses) + varicella (2 doses) + annual flu**

---

**Clinical Pearls:**
- **Live vaccines = same day OR ≥28 days apart** (inactivated = any interval)
- **Live vaccines contraindicated if immunocompromised, pregnant**
- **Shingrix ≥50 years** (2 doses, inactivated, safe in immunocompromised)
- **PCV20 single dose ≥65 years** (preferred, lifelong protection)
- **Universal hepatitis B vaccination 19-59 years** (2024 update)
- **Tdap every pregnancy** (27-36 weeks) + Td booster every 10 years
- **HIV: MMR/varicella safe if CD4 ≥200**
- **Asplenia = PCV20 + MenACWY + MenB** (encapsulated bacteria)
- **Mild illness NOT a contraindication** (can vaccinate)
- **Wait 1-3 months after stopping immunosuppression** before live vaccines

**Media:** None

**Sources:** [CDC/ACIP 2024 - Adult immunization schedule], [IDSA 2024 - Vaccination guidelines]
